Short answer
Fulcrum Therapeutics, Inc. (FULC) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$26M
- −51.4% YoY · −38.6% QoQ
- EPS (diluted)
- −$0.34
- −21.4% YoY · −36.0% QoQ
Source: XBRL data from the Fulcrum Therapeutics, Inc. (FULC) Q2 2026 10-Q on SEC EDGAR. USD.
Fulcrum Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales
- Operating margin (loss) 100.0% vs 100.0% YoY; net loss $26.2M vs $17.3M
- Pociredir highest R&D spending at $5.2M; Losmapimod lowest at $0
- Cash, equivalents and securities $318.8M; operating cash outflow $34.8M vs $29.1M
- Pociredir discontinued; 85% workforce reduction and strategic-alternatives review underway
Risk Factors
- New strategic-alternatives risk triggered by June 2026 pociredir discontinuation, including potential transaction costs and no assured outcome
- Most material operational change: workforce reduced 85%, from 57 to nine employees, potentially hindering strategic transactions
- Regulatory risk: FDA identified no viable pociredir path after malignancy concerns linked to PRC2 inhibition and Tazverik observations
- Near-term business risk: no product candidates remain in active clinical development following pociredir discontinuation
- Liquidity risk: $318.8 million in cash, equivalents, and marketable securities projected to fund operations into 2029, subject to changing assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulcrum Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.